Analyst’s Recommendation on: Titan Pharmaceuticals Inc. (TTNP)

The shares of Titan Pharmaceuticals Inc. (NASDAQ:TTNP) currently has mean rating of 2.00 while 0 analysts have recommended the shares as “BUY”, 2 recommended as “OUTPERFORM” and 0 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun 16 is 15.00M by 1 analysts. The means estimate of sales for the year ending Dec-16 is 15.40M by 2 analysts.

The mean price target for the shares of Titan Pharmaceuticals Inc. (TTNP) is at 10.00 while the highest price target suggested by the analysts is 10.00 and low price target is 10.00. The mean price target is calculated keeping in view the consensus of 1 brokerage firms.

The average estimate of EPS for the current fiscal quarter for Titan Pharmaceuticals Inc. (TTNP) stands at 0.56 while the EPS for the current year is fixed at 0.28 by 2 analysts.

The next one year’s EPS estimate is set at -0.29 by 1 analysts while a year ago the analysts suggested the company’s EPS at 0.28.

In its latest quarter ended on 31^st March 2016, Titan Pharmaceuticals Inc. (TTNP) reported earnings of $-0.09. The posted earnings topped the analyst’s consensus by $0.03 with the surprise factor of 25.00%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On May 26, 2016 Titan Pharmaceuticals Inc. (TTNP) announced that the U.S. Food and Drug Administration has approved Probuphine® (buprenorphine) implant, the first product for the long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or less a day of oral buprenorphine. The Probuphine subdermal implant, which utilizes Titan’s proprietary ProNeura™ technology, delivers buprenorphine continuously for up to six months. The product is expected to be commercially available this summer and is recommended for use as part of a complete treatment program including counseling and psychosocial support.

“The approval of Probuphine marks a major milestone for Titan and we look forward to supporting our partner Braeburn Pharmaceuticals during the product launch this summer,” said Titan President and CEO Sunil Bhonsle. “At a time when the government is supporting the expansion of access to opioid addiction treatments, the launch of Probuphine will provide the medical community with a novel, long-term treatment alternative that can provide benefits to many patients suffering from this disease.”